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MMAS-8Abstract Warfarin is a commonly prescribed oral anticoagulant in Saudi Arabia and yet patient
adherence to warfarin therapy and its impact on anticoagulation control have not been well
researched here. A cross-sectional survey was conducted over 6 weeks at the outpatient anticoagu-
lant clinic on patients who were receiving warfarin. Adherence was assessed using the translated
Arabic version of the Morisky Medication Adherence Scale (MMAS-8). Levels of adherence were
classed as low (score 6 7), or high (score = 8) based on the scores. Good anticoagulation control
was deﬁned as percent Time INR in Therapeutic Range (TTR)P 75% using the Rosendaal
method. A total of 192 patients completed a questionnaire with a response rate of 68.1%. It was
established that no association was found between adherence to warfarin therapy and INR control
groups. Among the 89 (46.4%) patients who had high adherence, only 34 (38.2%) had an accept-
able INR control. This was versus 103 (53.6%) patients who had low adherence but also 34 (33.0%)
had good INR control. Multivariate logistic regression (MLR) analysis showed that when studying
females and occupational status of unemployment, they were independently associated with poor
INR control with an OR 2.31, 95% CI 1.10–4.92, and OR 2.71, 95% CI 1.12–6.61 respectively.
MLR analysis also showed that age <50 years alongside no formal education was independently
associated with low adherence to warfarin therapy with an OR 2.67, 95% CI 1.29–5.52 and OR
2.63, 95% CI 1.01–6.93 respectively. The demographic background inﬂuences adherence and
INR control, but no association was found between adherence and anticoagulation control.
ª 2015 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Poor adherence to medication use is one of the greatest chal-
lenges for the improvement of health outcomes (World
Health Organization, 2003). Non-adherence to medications is
ongoing as patients receive more medications to treat their
chronic medical conditions. This is also apparent in the elderly
population due to a decline in their mental and physical health
(Gurwitz et al., 2003). The outcome of poor adherence to med-
ications can be life threatening with certain drugs like warfarin
30 A.Y. Mayetwhich has very narrow therapeutic index (Woodwell and
Cherry, 2004). The drug is used as a long-term oral anticoagu-
lation to prevent thromboembolic complications of various
conditions including stroke; atrial ﬁbrillation; venous throm-
boembolism; and valvular heart disease (Rose et al., 2009;
Wysowski et al., 2007). Warfarin is effective when the thera-
peutic range is maintained, but when the levels are below or
above the intended range, it is associated with increased risk
of thrombosis and bleeding, respectively (Hylek et al., 1996).
Poor adherence to warfarin is common with one in ﬁve
doses taken incorrectly even in the setting of a dedicated antic-
oagulation clinic (Platt et al., 2010). A study showed that up to
92% of the patients could not adhere to warfarin therapy and
had under anticoagulation control. For each 10% increase in
non-adherence to warfarin, there was a 14% increase in the
risk of under-anticoagulation and caused signiﬁcantly higher
rates of morbidity and mortality (Kimmel et al., 2007). An
older age, low level of education status and unemployment sta-
tus were seen to be independent risk factors for nonadherence
to warfarin therapy (Cruess et al., 2010).
Several studies have demonstrated that in patients on
chronic warfarin therapy, adherence is one of the many factors
that can affect anticoagulation control. Davis et al. concluded
in their study that adequate adherence, as determined by the
Morisky survey, was signiﬁcantly associated with anticoagula-
tion control (Davis et al., 2005).
An association between patients’ adherence and anticoagu-
lation control has not been well researched in Saudi Arabia.
The study objective was to assess patient adherence to warfarin
treatment using the MMAS-8 Arabic translated version, antic-
oagulation control, and the association between adherence and
anticoagulation control. It will also help to identify factors
associated with poor adherence and anticoagulation control.
This study should help us to identify deﬁciencies and
opportunities for strategic initiatives to improve medication
adherence and INR control. It will be an imperative step
toward optimizing the anticoagulation care at our clinic.2. Materials and methods
This cross-sectional study was conducted in an outpatient
anticoagulation clinic of King Khalid University hospital in
Riyadh, Saudi Arabia. This was after receiving the institu-
tional review board of approval. The hospital is a tertiary care
hospital with a 1000-inpatient bed capacity. It provides medi-
cal services to Saudi citizens from all over the country. The
anticoagulant clinic offers follow-up services to all of our
discharged patients who are receiving anticoagulants. The
study lasted for a period of 6 weeks. All patients with an age
P16 years who were discharged from hospital on warfarin,
and were taking the drug and attending the outpatient
anticoagulant clinic at the King Khalid University Hospital
for P6 months were asked to partake in the study during a
regular clinic visit. The consent was taken from all participants
prior to starting the questionnaire. Researchers administered
the questionnaire face to face with the patients and recorded
the answers.
To obtain an INR which reﬂected the warfarin dose and to
obtain complete data, the following patients were excluded
from the study; if the patients had a disruption in warfarin
therapy for P5 days during the study period; if they werehospitalized for any reason during the study period; and if they
did not have four consecutive INR readings or had an
incomplete questionnaire.
Adherence was assessed using the Arabic version of the
Morisky Medication Adherence Scale (MMAS-8). The
MMAS-8 is a self-reported questionnaire that has been fre-
quently used because of its low levels in both cost and time
expenditure. Although earlier studies showed that the
self-report method was underestimating non-adherence when
compared with pill counts or biological assays, later studies
suggest that the self-report method provides a reasonably
accurate estimate of adherence. The MMAS-8 has been vali-
dated in many studies in patients with diabetes mellitus (Lee
et al., 2013), hypertension (Korb-Savoldelli et al., 2012), and
those taking warfarin (Wang et al., 2012). An 8-item self-re-
port scale measured medication-taking behavior (Morisky
et al., 2008, 1986). Items 1–7 were recorded as ‘yes/no’ dichoto-
mous responses (scored 0/1) and item 8 was recorded using a 5-
point Likert scale (never/rarely scored 1, other responses
scored 0; Table 4). Thus, the total score of the 8-item scale
ranges from 0 to 80 and a total score of 8 was considered to
represent high adherence and scores 67 were considered as
low-adherence.
The translation to Arabic language for MMAS-8 was done
by using ‘‘The Eight Steps Translation Process’’ that combined
the recommendations of WHO (World Health Organization,
2007) and (Brislin, 1986) after placing ‘‘warfarin’’ in each item.
To assess the anticoagulation control, the most recent con-
secutive four INR readings, at an average of 4 weeks apart
were obtained from the hospital central laboratory electronic
data system for each patient. Anticoagulation control was
deﬁned as INR between 2P 3.0 for all indications except for
mitral valve replacement (2.5–3.5): Good INR control was
deﬁned as percent Time INR in Therapeutic Range
(TTR)P 75% during study period using the Rosendaal
method (Rosendaal et al., 1993). Previous studies had consid-
ered TTRP 75% as good INR control (Davis et al., 2005;
Wang et al., 2013).
Sensitivity and speciﬁcity of the MMAS-8 were calculated
to determine the usefulness of the scale in identifying patients
with poor anticoagulation control. Internal consistency of the
MMAS-8 was measured using Cronbach’s a with correlated
item-total correlations.
The questionnaire was validated in a crossover pilot study
conducted on 25 patients who were currently using warfarin
from the same clinic. It was done on two separate occasions,
and two weeks apart to avoid duplication of their ﬁrst
responses and the Cronbach’s a was calculated. The value
was 0.76 with moderate reliability.
Descriptive statistics (means, standard deviation, median,
range, counts and percentages) were used to describe the
quantitative and categorical study variables. Pearson’s Chi-
square tests and Fisher’s exact test were used to detect if there
were any associations between demographic characteristics,
adherence and anticoagulation control. Univariate odds ratios
were calculated between the categorical study and outcome
variables were calculated to measure the strength of associa-
tion. Multivariate binary logistic regression analysis was used
to ﬁnd out the independent associated variables among demo-
graphic background relating to adherence and anticoagulation
control. A p-value of <0.05 and 95% conﬁdence intervals
were used to report the statistical signiﬁcance and precision
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Statistical Package for Social Science (SPSS) software (SPSS
Inc., Chicago, IL), version 18.0.
3. Results
Three hundred and ten patients were invited to interview at the
outpatient anticoagulation clinic during study period. Two
hundred and eleven patients accepted the interview, which
gave a response rate of 68.1%. Nineteen patients were
excluded from the analysis due to the following reasons:
incomplete INR results (4); disruption in warfarin therapy
(6); and a substantial number of survey questions were not dis-
closed (9). The demographic and other patient characteristics
of the 192 subjects are summarized in relation to their adher-
ence and level of anticoagulation control in Table 1.
The mean age of the study population was 53.8 years
(SD ± 15.2). Among the 192 participants, 129 (67.2%) were
female, 136 (71.2%) were aged 50 and above, 163 (86.7%) were
non-smokers and 145 (77.5%) were married. Sixty participants
(31.4%) had not had any formal education and only 40
(20.9%) had a university diploma. Seventy-six participants
(39.8%) participants stated they had a job, and the remainders
were unemployed or dependents (Table 1).3.1. Adherence to warfarin treatment
The mean score for the medication adherence scale was 6.78
SD ± 1.22, and median score was 7 (range 1–8). The meanTable 1 Association between demographic factors and adherence t
Characteristics Total Low adherenc
combined (n,
Age
<50 years 55 37 (67.3)
P50 years 136 66 (48.5)
Gender
Male 63 31 (49.2)
Female 129 72 (55.8)
Marital status
Married 145 76 (52.4)
Others (unmarried, divorced/widow) 47 27 (57.4)
Education
No formal education 60 41 (68.3)
Primary/middle school 91 39 (42.9)
Diploma/university 40 23 (57.5)
Occupational status
Employed 76 38 (50.0)
Unemployed 50 29 (58.0)
Dependent 65 35 (53.8)
Smoking status
Previous or current smoker 25 15 (60.0)
Non smoker 163 87 (53.4)
Independent variable associated with adherence to warfarin treatment (b
Variables Adjuste
Age < 50 2.67 (1.
Education (no formal education) 2.63 (1.ages were similar in the high and low-adherence groups, 53.6
SD ± 15.2, and 52.3 SD ± 14.6, respectively. Eighty-nine
patients (46.4%) reported to having high adherence (scored
8) and 103 (53.7%) had low adherence to warfarin therapy.
Univariate tests showed that when the age is less than
50 years (OR 2.56, 95% CI 1.16 – 5.56) it is associated signiﬁ-
cantly with low adherence (score 6 7) to warfarin therapy
(Table 1). Multivariate logistic regression analysis showed that
when the age was less than 50 (OR 2.67, 95% CI 1.29–5.52)
and the education status was no formal education (OR 2.63,
95% CI 1.01–6.93), it was independently associated with low
adherence (score 6 7) to warfarin therapy.
3.2. Anticoagulation control
The mean ± SD INR values obtained for four readings were
as follows: INR 1st reading 2.57, SD ± 0.87, range 0.93–
8.03; INR 2nd reading 2.56, SD ± 0.79, range 1.05–6.78;
INR 3rd reading 2.67, SD ± 0.86, range 0.92–6.74, and 4th
reading 2.73, SD ± 0.77, range 1.16–6.71. The mean INR fol-
low-up days were 121 SD ± 39. Only 68 (35.4%) of the par-
ticipants had good anticoagulation control (TTRP 75%)
during the study period. Of the 124 participants with poor
anticoagulation control (TTR < 75%), 51 (41.1%) patients
had INR values below the therapeutic range, and 73 (58.9%)
had INR values above therapeutic range. Univariate tests
showed the occupational status as unemployed (OR 2.56,
95% CI 1.16–5.56, p= 0.03), and females (OR 1.97, 95% CI
1.06–3.67, p= 0.02) were signiﬁcantly associated with poor
INR control (Table 2). Multivariate logistic regression analysiso warfarin treatment.
e
%)
High adherence
(n, %)
OR (95% CI) p value
18 (32.7) 2.18 (1.13, 4.20) 0.02
70 (51.5) 1.0 –
32 (50.8) 1.0
57 (44.2) 1.30 (0.71, 2.38) 0.39
69 (47.6) 1.0
20 (42.6) 1.23 (0.63, 2.38) 0.55
19 (31.7) 1.59 (0.69, 3.66) 0.27
52 (57.1) 0.55 (0.26, 1.18) 0.12
17 (42.5) 1.0 –
38 (50.0) 1.0 –
21 (42.0) 1.38 (0.67, 2.83) 0.38
30 (46.2) 1.17 (0.60, 2.26) 0.65
10 (40.0) 1.131 (0.56, 3.09) 0.54
76 (46.6) 1.0 –
y multivariate logistic regression analysis)
d odd ratio p value
29, 5.52) 0.008
01, 6.93) 0.049
32 A.Y. Mayetalso showed females (OR 2.31, 95% CI 1.10–4.92) and occupa-
tional status as unemployed (OR 2.71, 95% CI 1.12–6.61) were
independently associated with poor INR control.
3.3. Association between adherence to warfarin treatment and
anticoagulation control
No association was found between the MMAS category (high
and low adherence) and INR control groups (X2 = 2.12,
p= 0.347). Eighty-nine patients (46.4%) had high adherence
(score = 8), 34 (38.2%) had good INR control versus 103
(53.6%) patients who had low adherence (score 6 7) and 34
(33.0%) had good INR control (Table 3).
The sensitivity and speciﬁcity for MMAS-8 were deter-
mined using INR control as a gold standard. The MMAS-8
had a sensitivity of 55.7% (range 46.6%–64.7%), speciﬁcity
of 50.0% (37.6%–62.4%), positive predictive value of 66.9%
(47.0%–75.9%) and negative predictive value of 37.8% (range
28.1%–49.1%). The sensitivity means that 69 (55.6%) of 124Table 2 Association between demographic factors and anticoagula
Characteristics Total Poor INR contr
TTR< 75% (n,
Age
<50 55 37 (67.3)
>50 136 86 (63.2)
Gender
Male 63 34 (54.0)
Female 129 90 (69.8)
Marital status
Married 145 91 (62.8)
Others (unmarried, divorced/widow) 47 33 (70.2)
Education
No formal education 60 38 (63.3)
Primary/middle school 91 59 (64.8)
Diploma/university 40 26 (65.0)
Occupational status
Employed 76 42 (55.3)
Unemployed 50 38 (76.0)
Dependent 65 44 (67.7)
Smoking status
Previous or current smoker 25 16 (64.0)
Non smoker 163 105 (64.4)
Independent variable associated with anticoagulation control (by multiva
Variables Adjus
Gender (female) 2.31 (
Occupation (unemployed) 2.71 (
Table 3 Association between anticoagulation control and adherenc
Parameters Poor INR control TTR< 75% (n, %) Good I
Low adherence 69 (67.0) 34 (33.0
High adherence 55 (61.8) 34 (38.2
Total, n 124 (64.6) 68 (35.4patients who had poor INR control had low and medium
warfarin adherence while the speciﬁcity indicates that 34 (50%)
of 68 patients with good INR control had high adherence to
their medication. The positive predictive value indicates that
69 (55.6%) of 103 patients with low and medium adherence
had poor control whereas 55 (37.8%) of 89 patients with high
adherence had good INR control.
The analysis of response allocation to each of the questions
of the Arabic version of MMAS-8 is shown in Table 4. All the
participants were able to answer >75% of the MMAS-8 ques-
tions correctly. Cronbach’s a for internal consistency was 0.650
for the MMAS-8. The item-total correlation coefﬁcients were
greater than 0.3 and ranged from 0.305 to 0.685 (Table 4).
4. Discussion
This is the ﬁrst study to explore the patient adherence to war-
farin treatment using the MMAS-8 Arabic translated version
and further investigates the association between therapytion control.
ol
%)
Good INR control
TTRP 75% (n, %)
OR (95% CI) p value
18 (32.7) 1.19 (0.62, 2.32) 0.59
50 (36.8) 1.0 –
29 (46.0) 1.0 –
39 (30.2) 1.97 (1.06, 3.67) 0.03
54 (37.2) 1.0 –
14 (29.8) 1.40 (0.69, 2.84) 0.35
22 (36.7) 0.93 (0.40, 2.14) 0.86
32 (35.2) 0.99 (0.45, 2.16) 0.98
14 (35.0) 1.0 –
34 (44.7) 1.0 –
12 (24.0) 2.56 (1.16, 5.65) 0.02
21 (32.3) 1.69 (0.85, 3.38) 0.13
9 (36.0) 0.98 (0.41, 2.36) 0.97
58 (35.6) 1.0 –
riate logistic regression analysis)
ted odd ratio p value
1.1, 4.92) 0.03
1.12, 6.61) 0.028
e to warfarin treatment.
NR control TTRP 75% (n, %) Total (n, %) X2, p value
) 103 (100) 2.12, (0.347)
) 89 (100)
) 192 (100)
Table 4 Responses from the eight-item Morisky medication adherence scale administered to patients who were on warfarin.
Items Patient responses Internal reliability
No Yes Corrected
item-total
correlation
Cronbach’s
alpha if item
deleted
1. Do you sometimes forget to take warfarin? (n= 192) 144 (75.0) 48 (25.0) 0.685 0.507
2. People sometimes miss taking their medicines for reasons other
than forgetting. Thinking over the past 2 weeks, were there any
days when you did not take your warfarin? (n= 192)
162 (84.4) 30 (15.6) 0.515 0.566
3. Have you ever cut back or stopped taking warfarin without
telling your doctor because you felt worse when you took it?
(n= 192)
176 (91.6) 16 (8.3) 0.409 0.597
4. When you travel or leave home, do you sometimes forget to
bring along your warfarin? (n= 192)
171 (89.1) 21 (10.9) 0.305 0.612
5. Did you take all your warfarin yesterday? (n= 192) 40 (20.8) 152 (79.2) 0.300 0.613
6. When you feel like your symptoms are under control, do you
sometimes stop taking your warfarin? (n= 192)
186 (96.9) 6 (3.1) 0.451 0.609
7. Taking medicine every day is a real inconvenience for some
people. Do you ever feel hassled about sticking to your
anticoagulation therapy? (n= 191)
157 (82.2) 34 (17.8) 0.274 0.616
Item 8 Never Once Sometimes Usually 0.511 0.604
8. How often do you have diﬃculty remembering to take your
warfarin? (n= 187)
153 (81.8) 8(4.3) 7 (3.7) 19 (10.2)
Patient adherence to warfarin therapy and its impact 33adherence and anticoagulation control (INR) in the Saudi
population. The mean adherence score of the study was 6.78
SD ± 1.22, it had a high-adherence rate of 46.4% and a good
INR control rate of 35.4%. The ﬁndings are consistent with a
study recently conducted in Singapore to investigate the adher-
ence of warfarin treatment in 174 patients using Chinese and
English versions of MMAS-8. The mean adherence score for
the MMAS-8 was 7.0 SD ± 1.1, a high-adherence rate
(score = 8) of 34.5%, and a good INR control (P80%) of
39.1% (Wang et al., 2013). Also, a study conducted in 2013
in Saudi Arabia using Arabic versions of MMAS-8 to examine
adherence to long-term medications in 408 patients with
chronic medical conditions. Their results showed 56.9% of
participants had good medication adherence (score = 8) that
is similar to that observed in the current study (Alhewiti,
2014). Furthermore, studies performed in patients of other
ethnic groups taking warfarin have reported approximately
80–90% adherence using methods other than MMAS-8 to
assess adherence (Orensky and Holdford, 2005; Parker et al.,
2007). On the contrary, a Korean study reported less than
30% of their studied group could adhere to prescribed med-
ications. They did not use Morisky scale to assess the warfarin
adherence. The medication adherence was characterized by
how well patients were following warfarin instruction (frequency,
dosage, time, and precautions) that had been given to them
(Kim et al., 2011).
The current study did not ﬁnd high adherence (46.3%) to
warfarin therapy that contributed to good INR control
(35.4%) in patients attending the outpatient clinic. The
association between warfarin therapy adherence and anticoa-
gulation control in the literature varies. Davis et al. had
noticed a signiﬁcant association between medication adherence
and good anticoagulation control by using Morisky scale.Fourteen percent of their patients achieved good INR control
(P70%) and 50% of patients had adequate adherence to war-
farin treatment. However, the study sample size was small with
only 52 participants, and the TTR% was calculated on an INR
result obtained within 60 days prior to survey completion. It
was half of the current study follow-up of 120 days (Davis
et al., 2005). A study from Singapore by Wang et al. in 2012
also reported a signiﬁcant association between anticoagulation
control and warfarin adherence. The study consisted of 151
patients, using English and Chinese versions of MMAS-8 to
assess the adherence. The mean score for adherence was 7.0;
one-third of patients had the highest adherence (score = 8)
and showed a signiﬁcant association between a high-adherence
score and TTR 6 80% (p= 0.01). However the study did not
mention how TTR and the TTR percent were calculated on an
INR result obtained only within 14 days prior to survey com-
pletion. This was much shorter than our study follow-up of
120 days (Wang et al., 2012). On the contrary, Kim et al.’s
cross-sectional survey could not associate between adherence
and anticoagulation control. However, the study did not use
the Morisky scale to assess the medication adherence. The
adherence was assessed by how well patients followed warfarin
instruction given to them (Kim et al., 2011).
The MMAS-8 Arabic translated version of the study had
moderate reliability in patients taking warfarin with
Cronbach’s a of 0.65 which is greater than 0.5, and is an
acceptable value (Nunnally and Bernstein, 1994; Streiner and
Norman, 2008). The MMAS-8 had been validated in different
languages in patients with hypertension, diabetes mellitus, and
those taking warfarin and though the results were varied
(Cronbach’s a 0.53–0.84) they were considered as moderately
reliable (Korb-Savoldelli et al., 2012; Sakthong et al., 2009;
Wang et al., 2012). Corrected item-total correlation coefﬁcient
34 A.Y. Mayetvalue was > 0.3, indicating that the Arabic version of MMAS-
8 had good homogeneity. The MMAS-8 had poor sensitivity
and speciﬁcity (55.7%, 50.0%) in the current study.
Although previous studies suggested that the self-report
method (MMAS-8) may provide cost effective and reasonably
accurate estimate of adherence, this method needs to compare
with other well-known used tools such as prescription reﬁlls,
pill counts or direct observation of therapy in the Middle
East countries to reach an appropriate conclusion. Wang
et al reported the MMAS-8 in patients taking warfarin had
sensitivity and speciﬁcity of 73.0% and 35.6% (Wang et al.,
2012). The study did not mention the method of calculating
the TTR percent for INR. The INR record obtained for the
past two weeks prior to survey administration was used to
deﬁne percent TTRP 80%.
The study had following limitations; its small sample size;
the cross-sectional methodology; and a lack of fully validated
instruments. Respondents in this study were recruited from an
outpatient anticoagulant clinic therefore the results cannot be
generalized to all patients.
5. Conclusion
The current level of adherence to warfarin therapy in our
patients is reasonable. No association was found between
adherence to warfarin therapy and anticoagulation control.
The MMAS-8 has moderate reliability in patients taking war-
farin, but the psychometric properties of the scale need to be
investigated in other clinical settings. Additional studies that
can recognize factors predicting favorable anticoagulation
control are also required.
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